Ibrutinib Shows Efficacy for the Treatment of Untreated and Relapsed/Refractory CLL
Single-agent ibrutinib (Imbruvica) data showed durable responses in patients with untreated or relapsed/refractory chronic lymphocytic leukemia (CLL).
Read More
Novel Therapies Show Promise in Mantle Cell Lymphoma
New combination strategies are required for heterogeneity of mantle cell lymphoma (MCL), in order to improve outcomes.
Immune Checkpoint Inhibitors in Lymphoma Spark Enthusiasm and Questions
Clinical evaluation suggests a role for immune checkpoint inhibition in the treatment of patients with lymphomas, but early success has also raised many questions.